| Item Type | Name |
|
Concept
|
Adrenal Cortex Hormones
|
|
Concept
|
Antigen-Antibody Complex
|
|
Concept
|
Arachidonate 5-Lipoxygenase
|
|
Concept
|
Antineoplastic Agents
|
|
Concept
|
Androstadienes
|
|
Concept
|
Angiotensin-Converting Enzyme Inhibitors
|
|
Concept
|
Anticoagulants
|
|
Concept
|
Anti-Inflammatory Agents, Non-Steroidal
|
|
Concept
|
Antimetabolites, Antineoplastic
|
|
Concept
|
Antibodies, Monoclonal
|
|
Concept
|
Base Sequence
|
|
Concept
|
Cefoxitin
|
|
Concept
|
Benzoates
|
|
Concept
|
Autoantigens
|
|
Concept
|
Benzodiazepines
|
|
Concept
|
Biological Products
|
|
Concept
|
Butadienes
|
|
Concept
|
Carcinogens
|
|
Concept
|
Flavonoids
|
|
Concept
|
Cisplatin
|
|
Concept
|
Leucovorin
|
|
Concept
|
C-Reactive Protein
|
|
Concept
|
Dermatologic Agents
|
|
Concept
|
Dactinomycin
|
|
Concept
|
DNA-Binding Proteins
|
|
Concept
|
Drug Synergism
|
|
Concept
|
Immunosuppressive Agents
|
|
Concept
|
DNA, Neoplasm
|
|
Concept
|
Heparin, Low-Molecular-Weight
|
|
Concept
|
Enzyme Inhibitors
|
|
Concept
|
Exons
|
|
Concept
|
Eye Proteins
|
|
Concept
|
DNA
|
|
Concept
|
Drug Resistance
|
|
Concept
|
Drug Therapy, Combination
|
|
Concept
|
Indoles
|
|
Concept
|
Introns
|
|
Concept
|
Fluorouracil
|
|
Concept
|
Coloring Agents
|
|
Concept
|
Dose-Response Relationship, Drug
|
|
Concept
|
Maleimides
|
|
Concept
|
Membrane Proteins
|
|
Concept
|
Leukotriene B4
|
|
Concept
|
Poly(ADP-ribose) Polymerases
|
|
Concept
|
Prothrombin
|
|
Concept
|
Organoplatinum Compounds
|
|
Concept
|
Methotrexate
|
|
Concept
|
Nerve Growth Factors
|
|
Concept
|
Nitriles
|
|
Concept
|
Nitrobenzenes
|
|
Concept
|
Masoprocol
|
|
Concept
|
Safety
|
|
Concept
|
Penicillanic Acid
|
|
Concept
|
Nitrosamines
|
|
Concept
|
Protein-Tyrosine Kinases
|
|
Concept
|
Immunoglobulin G
|
|
Concept
|
Receptors, Androgen
|
|
Concept
|
Protein Kinases
|
|
Concept
|
Quinolines
|
|
Concept
|
Reagent Kits, Diagnostic
|
|
Concept
|
Cadherins
|
|
Concept
|
Serpins
|
|
Concept
|
Stilbenes
|
|
Concept
|
Technetium Tc 99m Sulfur Colloid
|
|
Concept
|
Thymidine
|
|
Concept
|
Proto-Oncogene Proteins pp60(c-src)
|
|
Concept
|
Lipoxygenase Inhibitors
|
|
Concept
|
Biomarkers, Tumor
|
|
Concept
|
Tumor Necrosis Factor-alpha
|
|
Concept
|
Trisaccharides
|
|
Concept
|
Antigens, Tumor-Associated, Carbohydrate
|
|
Concept
|
HLA-C Antigens
|
|
Concept
|
CD11 Antigens
|
|
Concept
|
Radiopharmaceuticals
|
|
Concept
|
Mitogen-Activated Protein Kinases
|
|
Concept
|
Culture Media, Conditioned
|
|
Concept
|
Antigens, Nuclear
|
|
Concept
|
Receptors, Tumor Necrosis Factor
|
|
Concept
|
Receptors, Leukotriene B4
|
|
Concept
|
CA-19-9 Antigen
|
|
Concept
|
Interleukin-12
|
|
Concept
|
Inhibitor of Apoptosis Proteins
|
|
Concept
|
Angiogenesis Inhibitors
|
|
Concept
|
Cancer Vaccines
|
|
Concept
|
Cyclooxygenase 2 Inhibitors
|
|
Concept
|
Caspase 3
|
|
Concept
|
Caspase 7
|
|
Concept
|
cdc25 Phosphatases
|
|
Concept
|
MAP Kinase Kinase Kinases
|
|
Concept
|
eIF-2 Kinase
|
|
Concept
|
Leukotriene Antagonists
|
|
Concept
|
Receptors, Interleukin-17
|
|
Concept
|
Interleukin-23
|
|
Concept
|
Mucin 5AC
|
|
Concept
|
Cystic Fibrosis Transmembrane Conductance Regulator
|
|
Concept
|
Matrix Metalloproteinase 2
|
|
Concept
|
PPAR gamma
|
|
Concept
|
Green Fluorescent Proteins
|
|
Concept
|
bcl-2-Associated X Protein
|
|
Concept
|
Mitogen-Activated Protein Kinase 3
|
|
Concept
|
Proto-Oncogene Proteins c-bcl-2
|
|
Concept
|
Tissue Inhibitor of Metalloproteinase-1
|
|
Concept
|
Cyclin B
|
|
Concept
|
Cell Cycle Proteins
|
|
Concept
|
Proto-Oncogene Proteins c-kit
|
|
Concept
|
RNA Helicases
|
|
Concept
|
Nucleic Acid Synthesis Inhibitors
|
|
Concept
|
Bone Morphogenetic Proteins
|
|
Concept
|
Matrix Metalloproteinase 9
|
|
Concept
|
Cyclin-Dependent Kinase Inhibitor p21
|
|
Concept
|
Phosphopyruvate Hydratase
|
|
Concept
|
Polyethylene Glycols
|
|
Concept
|
Promoter Regions, Genetic
|
|
Concept
|
Protein Kinase C
|
|
Concept
|
RNA, Double-Stranded
|
|
Concept
|
Serum Albumin
|
|
Concept
|
RNA, Messenger
|
|
Concept
|
Sulfonamides
|
|
Concept
|
Antibodies, Monoclonal, Humanized
|
|
Concept
|
Apigenin
|
|
Concept
|
Steroids
|
|
Concept
|
Vitamin D
|
|
Concept
|
Cyclooxygenase 2
|
|
Concept
|
CDC2 Protein Kinase
|
|
Concept
|
Safety-Based Drug Withdrawals
|
|
Concept
|
Tetradecanoylphorbol Acetate
|
|
Concept
|
Thymidylate Synthase
|
|
Concept
|
Cyclosporine
|
|
Concept
|
Yttrium Radioisotopes
|
|
Concept
|
Proto-Oncogene Proteins p21(ras)
|
|
Concept
|
Proliferating Cell Nuclear Antigen
|
|
Concept
|
Cyclin E
|
|
Concept
|
Mitogen-Activated Protein Kinase 1
|
|
Concept
|
Interleukin-17
|
|
Concept
|
Mucin-2
|
|
Concept
|
Receptors, Calcitriol
|
|
Concept
|
Mucin-1
|
|
Concept
|
Ki-67 Antigen
|
|
Concept
|
Phosphatidylinositol 3-Kinases
|
|
Concept
|
Cyclin A
|
|
Concept
|
Untranslated Regions
|
|
Concept
|
Nuclear Matrix-Associated Proteins
|
|
Concept
|
Hepatocyte Nuclear Factor 1-beta
|
|
Concept
|
DEAD-box RNA Helicases
|
|
Concept
|
Keratin-19
|
|
Concept
|
Cornified Envelope Proline-Rich Proteins
|
|
Concept
|
Class II Phosphatidylinositol 3-Kinases
|
|
Concept
|
RNA, Small Interfering
|
|
Concept
|
Vascular Endothelial Growth Factor A
|
|
Concept
|
Cytochromes c
|
|
Concept
|
Depsipeptides
|
|
Concept
|
Cyclin-Dependent Kinase Inhibitor p27
|
|
Concept
|
Receptor, Notch1
|
|
Concept
|
Cyclin B1
|
|
Concept
|
Anti-Bacterial Agents
|
|
Concept
|
Antineoplastic Agents, Phytogenic
|
|
Concept
|
Camptothecin
|
|
Concept
|
Carcinoembryonic Antigen
|
|
Concept
|
Deoxycytidine
|
|
Concept
|
Drug Eruptions
|
|
Concept
|
Drug Administration Schedule
|
|
Concept
|
Factor V
|
|
Concept
|
Neoplasm Proteins
|
|
Concept
|
Nuclear Proteins
|
|
Concept
|
Piperacillin
|
|
Concept
|
Tumor Suppressor Protein p53
|
|
Concept
|
Mitomycin
|
|
Concept
|
Hyaluronan Receptors
|
|
Concept
|
Protein Isoforms
|
|
Concept
|
MicroRNAs
|
|
Concept
|
Protein Kinase Inhibitors
|
|
Concept
|
Bone Density Conservation Agents
|
|
Concept
|
Cyclin-Dependent Kinase 2
|
|
Concept
|
Caspase 9
|
|
Concept
|
Proton Pump Inhibitors
|
|
Concept
|
Growth Differentiation Factor 15
|
|
Concept
|
Drug Substitution
|
|
Academic Article
|
Eastern Cooperative Oncology Group Phase I trial of protracted venous infusion fluorouracil plus weekly gemcitabine with concurrent radiation therapy in patients with locally advanced pancreas cancer: a regimen with unexpected early toxicity.
|
|
Academic Article
|
A novel anti-pancreatic cancer agent, LY293111.
|
|
Academic Article
|
Identification and in silico characterization of a novel gene: TPA induced trans-membrane protein.
|
|
Academic Article
|
A multi-institutional phase II trial of preoperative full-dose gemcitabine and concurrent radiation for patients with potentially resectable pancreatic carcinoma.
|
|
Academic Article
|
Apigenin inhibits pancreatic cancer cell proliferation through G2/M cell cycle arrest.
|
|
Academic Article
|
Unresectable chemorefractory liver metastases: radioembolization with 90Y microspheres--safety, efficacy, and survival.
|
|
Academic Article
|
LY293111 improves efficacy of gemcitabine therapy on pancreatic cancer in a fluorescent orthotopic model in athymic mice.
|
|
Academic Article
|
A novel peptide sansalvamide analogue inhibits pancreatic cancer cell growth through G0/G1 cell-cycle arrest.
|
|
Academic Article
|
Phase II trial of full-dose gemcitabine and bevacizumab in combination with attenuated three-dimensional conformal radiotherapy in patients with localized pancreatic cancer.
|
|
Academic Article
|
Patients with moderate to severe plaque psoriasis: one year after the European Medicines Agency recommendation of efalizumab suspension.
|
|
Academic Article
|
Long-term follow-up of a Phase II trial of high-dose radiation with concurrent 5-fluorouracil and cisplatin in patients with anal cancer (ECOG E4292).
|
|
Academic Article
|
Randomized phase II study of gemcitabine plus radiotherapy versus gemcitabine, 5-fluorouracil, and cisplatin followed by radiotherapy and 5-fluorouracil for patients with locally advanced, potentially resectable pancreatic adenocarcinoma.
|
|
Academic Article
|
Leukotriene B4 receptor antagonist LY293111 induces S-phase cell cycle arrest and apoptosis in human pancreatic cancer cells.
|
|
Academic Article
|
Addition of algenpantucel-L immunotherapy to standard adjuvant therapy for pancreatic cancer: a phase 2 study.
|
|
Academic Article
|
Pancreatic cancer and FOLFIRINOX: a new era and new questions.
|
|
Academic Article
|
HLA-C*18:01: A Rare Allele in the European Caucasian Population Coinciding with Difficult-to-Treat Plaque Psoriasis.
|
|
Academic Article
|
The vitamin D receptor gene as a determinant of survival in pancreatic cancer patients: Genomic analysis and experimental validation.
|
|
Academic Article
|
Psoriasis Area and Severity Index response in moderate-severe psoriatic patients switched to adalimumab: results from the OPPSA study.
|
|
Academic Article
|
Primary systemic therapy in resectable pancreatic ductal adenocarcinoma using mFOLFIRINOX: A pilot study.
|
|
Academic Article
|
Clinical and histopathological characterization of eczematous eruptions occurring in course of anti IL-17 treatment: a case series and review of the literature.
|
|
Concept
|
Zonula Occludens-2 Protein
|
|
Concept
|
Myeloid Cell Leukemia Sequence 1 Protein
|
|
Academic Article
|
Piperacillin-Tazobactam Compared With Cefoxitin as Antimicrobial Prophylaxis for Pancreatoduodenectomy: A Randomized Clinical Trial.
|